Lack of Electrocardiographic Effects of Deucravacitinib in Healthy Subjects
Anjaneya Chimalakonda, Bindu Murthy(Bristol-Myers Squibb (United States)), John Throup(Bristol-Myers Squibb (United States)), Randy Dockens(Bristol-Myers Squibb (United States)), Subhashis Banerjee(Bristol-Myers Squibb (United States)), Shalabh Singhal(Integrated BioTherapeutics (United States)), Bing He(Bristol-Myers Squibb (United States)), Raymond B. Darbenzio(Bristol-Myers Squibb (United States)), Ihab Girgis(Bristol-Myers Squibb (United States)), Urvi Aras(Bristol-Myers Squibb (Germany)), David Marchisin(Bristol-Myers Squibb (United States))
Cited by 12
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
|Annals of the Rheumatic Diseases|2022|212
Risk of Major Bleeding with Concomitant Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients Receiving Long‐Term Warfarin Therapy
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|93
Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1<i>H</i>)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119
|Journal of Medicinal Chemistry|2014|46
Adropin correlates with aging-related neuropathology in humans and improves cognitive function in aging mice
|npj Aging and Mechanisms of Disease|2021|35